News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amneal Pharmaceuticals Inc
(NY:
AMRX
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amneal Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at Upcoming Investor Conference
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
May 16, 2024
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts
May 06, 2024
Via
Benzinga
Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement
May 03, 2024
Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Amneal Pharmaceuticals: Q4 Earnings Insights
March 01, 2024
Via
Benzinga
Earnings Outlook For Amneal Pharmaceuticals
February 29, 2024
Via
Benzinga
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 03, 2024
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Amneal Reports First Quarter 2024 Financial Results
May 03, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
April 24, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
April 16, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report First Quarter 2024 Results on May 3, 2024
April 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
March 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
March 25, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?
March 01, 2024
Amneal Pharmaceuticals reveals Q4 2023 results with $616.98 million revenue, up 1% YoY. Despite an 8% drop in adjusted EBITDA, the company beats EPS expectations. Co-CEOs anticipate growth in 2024,...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
March 01, 2024
Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!
Via
InvestorPlace
Earnings Scheduled For March 1, 2024
March 01, 2024
Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on revenue of $71.72 million.
Via
Benzinga
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
March 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
February 27, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
6 reasons to buy Teva Pharmaceuticals stock sooner than later
February 26, 2024
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Amneal to Participate at Upcoming Investor Conference
February 13, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
January 31, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
January 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
January 04, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces Move to Nasdaq
December 15, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
December 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
December 01, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at Upcoming Investor Conferences
November 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.